We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

High Court Won't Hear Abilify Whistleblowers' FCA Claims

Law360 (May 29, 2018, 5:04 PM EDT) -- The U.S. Supreme Court said Tuesday it will not hear whistleblowers’ appeal of a Sixth Circuit finding that they haven’t demonstrated that pharmaceutical companies Bristol-Myers and Otsuka’s alleged off-label promotion for the anti-psychotic drug Abilify and use of kickbacks was part of a conspiracy to submit false claims.

The order leaves in place the appeals court’s majority decision not to revive former Bristol-Myers Squibb Co. sales representatives Joseph Ibanez and Jennifer Edwards’ False Claims Act suit, saying they hadn’t proven a link between alleged false statements and and claims submitted to the government.

The Supreme Court did not comment on the case...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Attached Documents

Related

Sections

Case Information

Case Title

Subscribers Only

Case Number

Subscribers Only

Court

Supreme Court

Nature of Suit

2890 Other Statutory Actions

Date Filed

April 6, 2018

Law Firms

Companies

Government Agencies